Ann M Hopkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8539218/publications.pdf

Version: 2024-02-01

42 papers 3,313 citations

304368 22 h-index 301761 39 g-index

44 all docs

44 docs citations

44 times ranked

4724 citing authors

#	Article	IF	Citations
1	Proinflammatory Cytokines Disrupt Epithelial Barrier Function by Apoptosis-Independent Mechanisms. Journal of Immunology, 2003, 171, 6164-6172.	0.4	793
2	Interferonâ€Î³ induces internalization of epithelial tight junction proteins via a macropinocytosisâ€like process. FASEB Journal, 2005, 19, 923-933.	0.2	319
3	Expression of Specific Markers and Particle Transport in a New Human Intestinal M-Cell Model. Biochemical and Biophysical Research Communications, 2000, 279, 808-813.	1.0	246
4	RhoA, Rac1, and Cdc42 exert distinct effects on epithelial barrier via selective structural and biochemical modulation of junctional proteins and F-actin. American Journal of Physiology - Cell Physiology, 2004, 287, C327-C335.	2.1	199
5	Rho kinase regulates tight junction function and is necessary for tight junction assembly in polarized intestinal epithelia. Gastroenterology, 2001, 121, 566-579.	0.6	186
6	Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function. Journal of Cell Science, 2003, 116, 725-742.	1.2	184
7	Modulation of tight junction structure and function by cytokines. Advanced Drug Delivery Reviews, 2000, 41, 303-313.	6.6	160
8	Treatment of Thoracic Esophageal Anastomotic Leaks and Esophageal Perforations with Endoluminal Stents: Efficacy and Current Limitations. Journal of Gastrointestinal Surgery, 2008, 12, 1168-1176.	0.9	154
9	JAMâ€A expression positively correlates with poor prognosis in breast cancer patients. International Journal of Cancer, 2009, 125, 1343-1351.	2.3	115
10	Desmoglein-2: A Novel Regulator of Apoptosis in the Intestinal Epithelium. Molecular Biology of the Cell, 2007, 18, 4565-4578.	0.9	105
11	Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Research, 2011, 13, R31.	2.2	104
12	ICAM-1: targeted docking for exogenous as well as endogenous ligands. Advanced Drug Delivery Reviews, 2004, 56, 763-778.	6.6	80
13	Tight Junctions: A Barrier to the Initiation and Progression of Breast Cancer?. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-16.	3.0	70
14	Lipid Raft Association Restricts CD44-Ezrin Interaction and Promotion of Breast Cancer Cell Migration. American Journal of Pathology, 2012, 181, 2172-2187.	1.9	66
15	A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Research, 2014, 16, R19.	2.2	58
16	Modulation of tight junction function by G protein-coupled events. Advanced Drug Delivery Reviews, 2000, 41, 329-340.	6.6	56
17	Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors. American Journal of Physiology - Renal Physiology, 2007, 292, G806-G817.	1.6	50
18	Myosin II regulates the shape of three-dimensional intestinal epithelial cysts. Journal of Cell Science, 2008, 121, 1803-1814.	1.2	49

#	Article	IF	CITATIONS
19	Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Annals of Translational Medicine, 2015, 3, 184.	0.7	49
20	Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue. Journal of Pharmacy and Pharmacology, 2010, 54, 341-347.	1.2	39
21	Lipid rafts are disrupted in mildly inflamed intestinal microenvironments without overt disruption of the epithelial barrier. American Journal of Physiology - Renal Physiology, 2012, 302, G781-G793.	1.6	32
22	Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Research, 2018, 20, 140.	2,2	25
23	Ductal barriers in mammary epithelium. Tissue Barriers, 2013, 1, e25933.	1.6	21
24	Adhesion in Physiological, Benign and Malignant Proliferative States of the Endometrium: Microenvironment and the Clinical Big Picture. Cells, 2018, 7, 43.	1.8	21
25	Epithelial cell spreading induced by hepatocyte growth factor influences paxillin protein synthesis and posttranslational modification. American Journal of Physiology - Renal Physiology, 2004, 287, G886-G898.	1.6	19
26	Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth. Cancer Letters, 2019, 440-441, 23-34.	3.2	17
27	Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species. Cellular Oncology (Dordrecht), 2018, 41, 35-46.	2.1	12
28	An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. Journal of Experimental and Clinical Cancer Research, 2011, 30, 45.	3.5	11
29	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774604.	1.4	11
30	Antibiotic Tetrocarcin-A Down-regulates JAM-A, IAPs and Induces Apoptosis in Triple-negative Breast Cancer Models. Anticancer Research, 2019, 39, 1197-1204.	0.5	11
31	Dynamic interplay between adhesion surfaces in carcinomas: Cell-cell and cell-matrix crosstalk. World Journal of Biological Chemistry, 2016, 7, 64.	1.7	9
32	A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer. Cells, 2022, 11, 735.	1.8	9
33	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	2.3	8
34	Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death and Disease, 2021, 12, 763.	2.7	8
35	Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1. Cancers, 2021, 13, 871.	1.7	7
36	C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency. Biomedicines, 2021, 9, 1925.	1.4	4

3

#	Article	IF	CITATIONS
37	Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression. Cancers, 2022, 14, 1303.	1.7	2
38	Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. Cancers, 2021, 13, 1286.	1.7	1
39	Cleaved JAM-A - connecting cancer and vascular disease?. Oncotarget, 2019, 10, 3831-3832.	0.8	1
40	The Contribution of Ig-Superfamily and MARVEL D Tight Junction Proteins to Cancer Pathobiology. Current Pathobiology Reports, 2016, 4, 37-46.	1.6	0
41	The Molecular Aspects of Tight Junctions. Cancer Metastasis - Biology and Treatment, 2013, , 1-27.	0.1	O
42	Tight Junction Protein Junctional Adhesion Molecule-A Regulates the Expression of Receptor Tyrosine Kinase EPHA2 In Triple-Negative Breast Cancer Cells. Clinical Oncology and Research, 2019, , .	0.1	0